MicroRNA-mRNA functional pairs for cisplatin resistance in ovarian cancer cells

Chinese Journal of Cancer

Volumn 33, Issue 6, 2014, Pages 285-294

  Liu, Mei ^a   Zhang, Xin ^b   Hu, Chen Fei ^a   Xu, Qing ^a   Zhu, Hong Xia ^a   Xu, Ning Zhi ^a  

^a CANCER HOSPITAL   (China)

^b Emergency Department   (China)

Author keywords

Cisplatin resistance; miRNA; Ovarian cancer; TP73

Indexed keywords

ANKYRIN; CISPLATIN; GENERAL TRANSCRIPTION FACTOR; MICRORNA; MICRORNA 100; MICRORNA 10A; MICRORNA 125B; MICRORNA 133A; MICRORNA 139 3P; MICRORNA 181C; MICRORNA 27B; MICRORNA 33A; MICRORNA 34A; MICRORNA 383; MICRORNA 486 3P; PROTEIN P73; SUMO 1 PROTEIN; UNCLASSIFIED DRUG; ANKRD17 PROTEIN, HUMAN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; GTF2H1 PROTEIN, HUMAN; MESSENGER RNA; NONHISTONE PROTEIN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; PROTEINASE; SENP1 PROTEIN, HUMAN; STRUCTURAL MAINTENANCE OF CHROMOSOME PROTEIN 1; TRANSCRIPTION FACTOR II; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DOWN REGULATION; DRUG RESPONSE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; MRNA EXPRESSION ASSAY; MTT ASSAY; OVARY CANCER; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DRUG RESISTANCE; FEMALE; OVARY TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; CISPLATIN; DNA-BINDING PROTEINS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ENDOPEPTIDASES; FEMALE; HUMANS; MICRORNAS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PHOSPHOPROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS, TFII; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84901792506     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10136     Document Type: Article

References (38)

1. Legge F, Ferrandina G, Salutari V, et al. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol, 2005,16 Suppl 4:iv95-iv101.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3:502-516.
3. Parker RJ, Eastman A, Bostick-Bruton F, et al. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest, 1991,87:772-777.
4. Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A, 1992,89:3070-3074.
5. Kelley SL, Basu A, Teicher BA, et al. Overexpression of metallothionein confers resistance to anticancer drugs. Science, 1988,241:1813-1815.
6. Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer, 2010,126:2-10.
7. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther, 2010,17: 523-31.
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004,116:281-97.
9. Ambros V. The functions of animal microRNAs. Nature, 2004,431:350-5.
10. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist Updat, 2007,10:59-67.
11. Blower PE, Chung JH, Verducci JS, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther, 2008,7:1-9.
12. Blower PE, Verducci JS, Lin S, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther, 2007,6:1483-1491.
13. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A, 1998,95:14863-14868.
14. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 2005,33:e179.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods, 2001,25:402-408.
16. Lewis BP, Shih IH, Jones-Rhoades MW, et al. Prediction of mammalian microRNA targets. Cell, 2003,115:787-798.
17. Vergoulis T, Vlachos IS, Alexiou P, et al. TarBase 6.0: capturing the exponential growth of miRNA targets with experimental support. Nucleic Acids Res, 2012,40:D222-D229.
18. Xiao F, Zuo Z, Cai G, et al. miRecords: an integrated resource for microRNA-target interact ions. Nucleic Acids Res, 2009,37:D105-D110.
19. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 2003,22:7265-7279.
20. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin, 2007,57:43-66.
21. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res, 2007,67:8699-8707.
22. Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A, 2008,105:7004-7009.
23. Laios A, O'Toole S, Flavin R, et al. Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer, 2008,7:35.
24. Boren T, Xiong Y, Hakam A, et al. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol, 2009,113:249-255.
25. Eitan R, Kushnir M, Lithwick-Yanai G, et al. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol, 2009,114: 253-259.
26. Yang N, Kaur S, Volinia S, et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res, 2008,68:10307-10314.
27. Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug resistant ovarian cancer cells. Gynecol Oncol, 2008,111:478-486.
28. Kumar S, Kumar A, Shah PP, et al. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res, 2011,4:17.
29. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 2008,68:425-433.
30. White NM, Chow TF, Mejia-Guerrero S, et al. Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer. Br J Cancer, 2010,102:1244-1253.
31. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods, 2006,3:881-886.
32. Ozaki T, Nakagawara A. p73, a sophisticated p53 family member in the cancer world. Cancer Sci, 2005,96:729-737.
33. Pogribny IP, Filkowski JN, Tryndyak VP, et al. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer, 2010,127:1785-1794.
34. Schotte D, De Menezes RX, Moqadam FA, et al. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica, 2011,96:703-711.
35. Zhu H, Wu H, Liu X, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol, 2008,76:582-588.
36. Grimson A, Farh KK, Johnston WK, et al. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell, 2007,27:91-105.
37. Husain A, He G, Venkatraman ES, et al. BRCA1 up-regulation is associated wi th repai r-mediated resistance to cisdiamminedichloroplatinum(II). Cancer Res, 1998,58:1120-1123.
38. Yan X, Yin J, Yao H, et al. Increased expression of annexin A3 is a mechanism of platinum resistance in ovarian cancer. Cancer Res, 2010,70:1616-1624.